BB-1701 — Investigational Agent
Antibody-Drug Conjugate · Phase 2 · Eisai / Bliss Biopharmaceutical
Mechanism of Action
An anti-HER2 antibody conjugated to eribulin, a microtubule dynamics inhibitor, delivering a non-topoisomerase payload to HER2-expressing tumor cells. The distinct payload class may retain activity after prior topoisomerase-based HER2 ADCs.
Investigational Indications
- HER2-positive metastatic breast cancer
- HER2-low metastatic breast cancer
- HER2-expressing solid tumors